Neurotherapeutics in the Era of Translational Medicine Speaker: Richard A. Smith, M.D.

Director, Center for Neurologic Study

La Jolla, California

Friday, November 12, 12:00 p.m. to 1:00 p.m. CDT

Event Link:

  • Access code: 2530 124 9830

  • Meeting password: MaFEGCwm653

Biogen and Ionis announced that BIIB080/IONIS-MAPTRx, an antisense drug, demonstrated robust time and dose-dependent lowering of tau protein in cerebrospinal fluid (CSF) over the three-month treatment period and sustained reductions during the six-month post-treatment period. Click here to learn more.

The lecture will be given in November at the Methodist Hospital (Houston). The invitation was extended by Dr. Stanley Appel, Chair of the Department of Neurology and Co-Director of the Methodist Neurological Institute.